THE BioMed Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system. In addition, the company offers immunodiagnostics products comprising VERI-Q COVID-19 Ag Rapid Test and VERI-Q COVID-19 IgGIgM Rapid Test for COVID testing; VERI-Q PinoView, a device for detecting markers of specific diseases through antigen-antibody reaction; and Opti96 ELISA plate/Kit. The company was formerly known as MiCo BioMed Co., Ltd. and changed its name to THE BioMed Co., Ltd. in May 2025. MiCo BioMed Co., Ltd. was founded in 2009 and is headquartered in Seongnam-si, South Korea.
South Korean Market Performance
7D7 Days: -1.6%
3M3 Months: 21.9%
1Y1 Year: 21.3%
YTDYear to Date: 30.7%
Over the last 7 days, the market has dropped 1.6%, driven by a pullback of 3.6% in the Information Technology sector. In the last year, the market is actually up 21%. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.